BLPH - ベレロフォン・セラピュ―ティクス （Bellerophon Therapeutics Inc.）

Bellerophon Therapeutics (BLPH) entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares…

WARREN, N.J., March 06, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. The offering is expected to close on March 7, 2023, subject to the satisfaction of customary closing conditions.

Bellerophon Therapeutics, Inc. , a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug … | February 10, 2023

China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint WARREN, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced clearance of its Investigational New Drug

China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint China NPMA accepts the use of Moderate to Vigorous Physical Activity (MVPA) as the primary endpoint

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Scienjoy Holding Corporation (NASDAQ: SJ ) climbed 47.9% to close at $2.47 after declining 44% on Monday. Sonendo, Inc. (NASDAQ: SONX ) gained 42.7% to close at $1.67. Sonendo recently announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million led by a consortium of new and existing investors. X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) gained 40.2% to close at $1.25 after the company announced data from its Phase 1b trial evaluating mavorixafor in chronic neutropenia. Antelope Enterprise Holdings Limited (NASDAQ: AEHL ) rose 37.5% to settle at $0.9320.

U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.22% to 29,196.13 while the NASDAQ rose 0.31% to 10,836.79. The S&P 500 also fell, dropping, 0.06% to 3,652.89. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 0.7% on Tuesday. In trading on Tuesday, utilities shares dipped by 2%. Top Headline New home sales jumped 28.8% from a month ago to a five-month high of 685,000 in August. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 170% to $9.52. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 27% to $2.7581 as the company issued a corporate update after IPO .

U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. The Dow traded down 1.60% to 29,085.07 while the NASDAQ fell 0.31% to 10,769.06. The S&P 500 also fell, dropping, 0.50% to 3,636.85. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 1.1% on Tuesday. In trading on Tuesday, utilities shares fell 1.8%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose 16.1% year-over-year in July. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 147% to $8.70. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 38% to $2.9894 as the company issued a corporate update after IPO .

Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD). The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints. The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.

The FDA has accepted Bellerophon Therapeutics Inc''s (NASDAQ: BLPH ) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD). The new study size of 140 subjects does not impact the trial''s … Full story available on Benzinga.com

Gainers Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares climbed 106.3% to close at $9.15. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Scienjoy Holding Corporation (NASDAQ: SJ ) climbed 47.9% to close at $2.47 after declining 44% on Monday. Sonendo, Inc. (NASDAQ: SONX ) gained 42.7% to close at $1.67. Sonendo recently announced a private placement of common stock and pre-funded warrants, resulting in gross proceeds of $63 million led by a consortium of new and existing investors. X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) gained 40.2% to close at $1.25 after the company announced data from its Phase 1b trial evaluating mavorixafor in chronic neutropenia. Antelope Enterprise Holdings Limited (NASDAQ: AEHL ) rose 37.5% to settle at $0.9320.

U.S. stocks pared some losses toward the end of trading, with the Nasdaq Composite turning higher on Tuesday. The Dow traded down 0.22% to 29,196.13 while the NASDAQ rose 0.31% to 10,836.79. The S&P 500 also fell, dropping, 0.06% to 3,652.89. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 0.7% on Tuesday. In trading on Tuesday, utilities shares dipped by 2%. Top Headline New home sales jumped 28.8% from a month ago to a five-month high of 685,000 in August. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 170% to $9.52. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 27% to $2.7581 as the company issued a corporate update after IPO .

U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 175 points on Tuesday. The Dow traded down 1.60% to 29,085.07 while the NASDAQ fell 0.31% to 10,769.06. The S&P 500 also fell, dropping, 0.50% to 3,636.85. Also check this: Market Volatility Increases Amid Another Drop On Wall Street Leading and Lagging Sectors Energy shares rose by 1.1% on Tuesday. In trading on Tuesday, utilities shares fell 1.8%. Top Headline The S&P CoreLogic Case-Shiller 20-city home price index rose 16.1% year-over-year in July. Equities Trading UP Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares shot up 147% to $8.70. Avenue Therapeutics recently received the official meeting minutes from the FDA regarding a meeting conducted for IV Tramadol in combination with other opioid analgesics to manage moderate-to-moderately severe pain. Concurrently, Avenue Therapeutics announced that it would effect a 1-for-15 reverse stock split. Shares of PaxMedica, Inc. (NASDAQ: PXMD ) got a boost, shooting 38% to $2.9894 as the company issued a corporate update after IPO .

Shares of clinical-stage company Bellerophon Therapeutics (NASDAQ:BLPH) are soaring high today after the U.S. Food and Drug Administration (FDA) agreed to a reduction in the size of BLPH’s Phase 3 study of INOpulse for treating fibrotic interstitial lung disease (fiLD). The data monitoring committee of the study supported lowering the study size to 140 from 300 and the change does not affect the trial’s principal objective or endpoints. The company expects to complete enrolment in Q1 2023 with top-line data expected in Q3 2023.

The FDA has accepted Bellerophon Therapeutics Inc''s (NASDAQ: BLPH ) proposal to reduce the study size for its ongoing registrational REBUILD Phase 3 trial of INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD). The new study size of 140 subjects does not impact the trial''s … Full story available on Benzinga.com